drugset
drugset / Trial / NCT05325346

A Phase I Study of the Co-administration of VLX-1005 and Argatroban in Healthy Human Subjects

NCT05325346 ↗

Phase 1 Completed 12 enrolled Veralox Therapeutics Celerion · collab
RandomizedCrossoverOpen-labelTreatment

Summary

The study is designed to characterize the safety and tolerability of VLX-1005 and argatroban administered intravenously, either alone or in combination; and the pharmacokinetics and pharmacodynamics and potential interaction of both agents in a population of healthy subjects.

Timeline

Start
2022-03-07
Primary completion
2022-04-01
Completion
2022-04-14

Drugs

EvaluationDrugModalityDoseRoute
Subject Argatroban Small molecule — Intravenous
Subject VLX-1005 Small molecule — Intravenous

Indications

heparin-induced thrombocytopenia